GENETIC TECHNOLOGIES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.12 AUD | -7.69% |
|
0.00% | -11.11% |
Presenter SpeechAdrian Mulcahy;Market Eye (Attendees)[Audio Gap] We have with us today, which ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Genetic Technologies Limited is an Australia-based diversified molecular diagnostics company. The Company is engaged in providing genomics-based tests on health, wellness and serious disease through its geneType and EasyDNA brands. The Company offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The Company has a proprietary risk stratification platform that integrates clinical and genetic risk to deliver outcomes to physicians and individuals. The Company operates through three segments: EasyDNA, AffinityDNA, and GeneType / Corporate. EasyDNA segment relates to EasyDNA branded test sales and expenses. AffinityDNA segment relates to AffinityDNA branded test sales and expenses. GeneType / Corporate segment relates to geneType branded test sales and expenses, including corporate charges. The GeneType test is for breast cancer, colorectal cancer, ovarian cancer, prostate cancer, coronary artery disease and mor
Calendar
2024-08-28
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -11.11% | 10.48M | |
| +20.68% | 85.55B | |
| -29.31% | 70.07B | |
| +9.23% | 29.06B | |
| -8.63% | 17.51B | |
| +2.14% | 17.39B | |
| +0.39% | 15.38B | |
| +6.47% | 13.4B | |
| +68.09% | 12.87B | |
| +6.43% | 12.77B |
- Stock Market
- Equities
- GTG Stock
- News Genetic Technologies Limited
- Transcript : Genetic Technologies Limited, Q1 2023 Earnings Call, Nov 03, 2022
